BIOQUELL’s ‘proactive’ hydrogen peroxide vapour (HPV) decontamination service has been chosen to be one of only six technologies to be placed in seven NHS showcase hospitals. The HCAI technology innovation programme is a new initiative set up by the DoH to develop, promote and press forward new technologies into our hospitals that have the potential to make a real difference in the battle against HCAI’s.
BIOQUELL’s experience in providing high level decontamination equipment and services has been rewarded with a DoH led contract that will see the patented Clarus® technology used as a proactive service within seven designated showcase hospitals over a four month trial period.
Matthew Parks, head of room bio-decontamination services at the Hampshire based company commented, "We are confident that the proactive service will prove to be a great success, just as they have been in similar deployments throughout the UK, Europe and America. We look forward to reviewing and promoting the results, with a goal to be working alongside all British hospitals in the near future".
BIOQUELL’s unique decontamination technology is supported by robust scientific data and is the only technology of its kind to be awarded category One status by the DoH’s expert rapid review panel. An article published online in July of this year (Boyce et al - Infection Control and Hospital Epidemiology 2008, in press.) proved a reduction in the acquisition of C. difficile infections whilst being operated within a busy healthcare setting.
Benefits of BIOQUELL’s HPV technology include: